2004
Urban JD , Gay EA, Mailman RB. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.
Topics: drug interactions
Urban JD , Gay EA, Mailman MM. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.
Grasty RC , Roberts N, Grey BE, Lau C, Rogers JM. (2004). Perfluorooctane sulfonate (PFOS) alters lung development in the neonatal rat. Birth Defects Research, Part A, 70(5), 42.
2003
Perry, C.S . Process for development of protective concentration levels for remediation sites in Texas.Presented at Society for Environmental Toxicology and Chemistry (SETAC) meeting. November 9-13, 2003. Austin, TX.
Staskal, D.F.
Staskal DF , DeVito MJ, Ross DG, Birnbaum LS. 2003. Caffeine, acetanilide, and methoxyresorufin metabolism by rat and human CYP1A2 SUPERSOMES and their inhibition by 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD). Organohalogen Compounds.
Topics: dioxin
Staskal DF 64:324-327 .
View Abstract
Topics: dioxin
Grasty RC , Grey BE, Lau CS, Rogers JM. 2003. Window of susceptibility to perfluorooctane sulfonate (PFOS)-induced neonatal mortality in the rat. Birth Defects Research, Part B, 68(3), 5.
2002
Perry, C.S. TRRP Rule – The basics part 2: human health PCLs and look-up tables. 2002 TNRCC Environmental Trade Fair presentation and paper.
Grasty RC , Grey BE, Thibodeaux J, Lau C, Rogers JM. (2002). Critical period for increased neonatal mortality induced by perfluorooctane sulfonate (PFOS) in the rat. The Toxicologist 66 (1-S), 118.
